Our findings so far show that three of the peptides SPEA agonists have similar profiles of the full superantigen SPEA in activating the T- cells and producing different types of cytokines with an anti-cancer effect such as IL-1, IL-6, and IL-10, as mentioned above (Figure 2 and Figure 3). This evidence concerns the gene IL1B and cancer.